This article provides a data-driven comparison of retatrutide (a triple GLP-1/GIP/glucagon receptor agonist in clinical trials) and tirzepatide (a dual GLP-1/GIP agonist approved as Mounjaro/Zepbound).

Mechanism of Action Comparison

Feature Retatrutide Tirzepatide
Receptor targets GLP-1, GIP, Glucagon (triple) GLP-1, GIP (dual)
Approval status Investigational (Phase 3 trials) FDA-approved (Mounjaro/Zepbound)
Dosing frequency Once weekly (subcutaneous) Once weekly (subcutaneous)
Half-life ~6 days ~5 days

Weight Loss Efficacy

Retatrutide (Phase 2 Data)

  • At 12 mg weekly (highest dose): mean weight loss of ~24.2% at 48 weeks
  • Clinically significant weight loss achieved at all doses tested (2 mg, 4 mg, 8 mg, 12 mg)
  • Phase 3 trials ongoing; final efficacy/safety data not yet available

Tirzepatide (Phase 3 / SURMOUNT Data)

  • At 15 mg weekly (highest approved dose): mean weight loss of ~22.5% at 72 weeks (SURMOUNT-1)
  • Up to ~26% weight loss in some subgroups
  • Approved for chronic weight management (Zepbound) and type 2 diabetes (Mounjaro)

Key Differentiating Factor: Glucagon Receptor Agonism

Retatrutide’s additional glucagon receptor agonism may provide:

  • Enhanced energy expenditure beyond GLP-1 and GIP effects alone
  • Potentially greater fat oxidation, particularly visceral fat
  • Possible benefits for non-alcoholic fatty liver disease (NAFLD)

However, glucagon agonism also increases the risk of hyperglycemia if not balanced appropriately with GLP-1/GIP effects.

Side Effect Profiles

Both agents share similar GI side effect profiles due to GLP-1 agonism:

  • Nausea (most common, typically dose-dependent and transient)
  • Vomiting
  • Diarrhea
  • Constipation
  • Decreased appetite

Current Status Summary

  • Tirzepatide: FDA-approved, commercially available, extensive Phase 3 safety/efficacy data
  • Retatrutide: Investigational only, promising Phase 2 data, Phase 3 ongoing, not commercially available

Disclaimer

This comparison is for educational purposes only. Retatrutide is not approved for human use. Tirzepatide (Mounjaro/Zepbound) requires a prescription from a licensed healthcare provider. Never use these compounds without appropriate medical supervision.